Tuesday, March 13, 2012

The Protein Engineering Summit next month at the Immunogenicity for Biotherapeutics event!

We are very pleased to offer extensive knowledge-sharing and networking opportunities at the 13th annual Immunogenicity for Biotherapeutics conference that will greatly boost your skills and confidence in your day-to-day responsibilities.

In addition to our main program, we are also offering several add-on summits that delve into far greater detail and feature more audience interactivity than is usually possible in a conference setting. By now you have already heard of our “Immunogenicity University” all-day intensive, but there is also another option available to you – for a limited time only!

We invite you to join our special summit to be held the morning of April 17th:

“Specific Strategies on Protein Engineering to Minimize Epitopes”
Harald Kropshofer, PhD
Facilitated by: Harald Kropshofer, PhD, Senior Personalized Healthcare Leader, F. Hoffman La Roche & Sathy Balu-Iyer, PhD, Associate Professor of Pharmaceutical Sciences, University Of Buffalo

This technical summit will help map the industry’s knowledge of tolerogenic mechanisms, and balance your arsenal of immunosuppressants with the proper advances in molecular re-engineering.
  • • Adapt to lessons from leading-edge gene therapy breakthroughs in order to suppress immune response in the most specific manner possible
  • • Manage adaptive immune response through deimmunization of proteins and peptides
  • • Use of peptide sequencing to clarify exactly how they are presented to T-cells. What are the impacts on immune response of natural vs. engineered presentations?

For more information on this Summit and the rest of the program, download the brochure here.  Immunogenicity of Biotherapeutics will be taking place April 17-19, 2012, in Baltimore, MD.  For an exclusive discount for the event, join the Immunogenicity for Biotherapeutics LinkedIn Group.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment